山河药辅:股东复星医药因经营需要拟减持不超过3%公司股份

观点网
23 Feb

观点网讯:山河药辅2月23日公告,股东上海复星医药产业发展有限公司因经营需要,计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股,即不超过公司总股本的3%。

山河药辅表示,公司生产经营情况正常。本次拟减持股份的股东不属于公司的控股股东或实际控制人,本次股份减持不会导致公司控制权发生变更,不会对公司治理结构、股权结构及持续性经营产生影响。

免责声明:本文内容与数据由观点根据公开信息整理,不构成投资建议,使用前请核实。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10